Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma - PubMed
2 days ago
- #B-NHL
- #Spatial Transcriptomics
- #CAR-T Therapy
- CD19/20 CAR-T therapy in relapsed/refractory B-NHL showed a 74% overall response rate, with 58% achieving complete remission.
- Median progression-free survival was 6.8 months, and overall survival was 22.1 months, with higher responses in patients with normal lactate dehydrogenase.
- Safety profile included 53% cytokine release syndrome (12% grade ≥3) and 9% immune effector cell-associated neurotoxicity syndrome (all grade 3), with no lasting deficits.
- CAR-T expansion peaked at days 7-17, with persistence exceeding 500 days in long-term responders.
- Spatial transcriptomics identified two tumor phenotypes: B-cell-dominant with apoptotic competence linked to remission, and fibroblast/monocyte-enriched with T-cell-permissive microenvironment.